Literature DB >> 11939242

The estimation of a preference-based measure of health from the SF-36.

John Brazier1, Jennifer Roberts, Mark Deverill.   

Abstract

This paper reports on the findings of a study to derive a preference-based measure of health from the SF-36 for use in economic evaluation. The SF-36 was revised into a six-dimensional health state classification called the SF-6D. A sample of 249 states defined by the SF-6D have been valued by a representative sample of 611 members of the UK general population, using standard gamble. Models are estimated for predicting health state valuations for all 18,000 states defined by the SF-6D. The econometric modelling had to cope with the hierarchical nature of the data and its skewed distribution. The recommended models have produced significant coefficients for levels of the SF-6D, which are robust across model specification. However, there are concerns with some inconsistent estimates and over prediction of the value of the poorest health states. These problems must be weighed against the rich descriptive ability of the SF-6D, and the potential application of these models to existing and future SF-36 data set.

Mesh:

Year:  2002        PMID: 11939242     DOI: 10.1016/s0167-6296(01)00130-8

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  933 in total

1.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

2.  The impact of tuberculosis on health utility: a longitudinal cohort study.

Authors:  Melissa Bauer; Sara Ahmed; Andrea Benedetti; Christina Greenaway; Marek Lalli; Allison Leavens; Dick Menzies; Claudia Vadeboncoeur; Bilkis Vissandjée; Ashley Wynne; Kevin Schwartzman
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

3.  The effect of weight loss on changes in health-related quality of life among overweight and obese women with urinary incontinence.

Authors:  Angela Marinilli Pinto; Leslee L Subak; Sanae Nakagawa; Eric Vittinghoff; Rena R Wing; John W Kusek; William H Herman; Delia Smith West; Miriam Kuppermann
Journal:  Qual Life Res       Date:  2011-12-10       Impact factor: 4.147

4.  Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.

Authors:  Mark Parker; Alan Haycox; Jane Graves
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

5.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

6.  EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.

Authors:  Mihir Gandhi; Marcus Ang; Kelvin Teo; Chee Wai Wong; Yvonne Chung-Hsi Wei; Rachel Lee-Yin Tan; Mathieu F Janssen; Nan Luo
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

7.  Cost-effectiveness of neuromuscular ultrasound in focal neuropathies.

Authors:  Ross Mandeville; Arvin Wali; Charlie Park; Erik Groessl; Francis O Walker; Michael S Cartwright
Journal:  Neurology       Date:  2019-05-03       Impact factor: 9.910

8.  Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?

Authors:  Michela Tinelli; Mandy Ryan; Christine Bond; Anthony Scott
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

9.  Impact of musculoskeletal disorders on quality of life: an inception cohort study.

Authors:  C H Roux; F Guillemin; S Boini; F Longuetaud; N Arnault; S Hercberg; S Briançon
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

10.  Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.

Authors:  Silas C Martin; Dennis D Gagnon; Lucy Zhang; Carsten Bokemeyer; Marinus Van Marwijk Kooy; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.